Camptothecin induces urokinase-type plasminogen activator gene-expression in human RC-K8 malignant lymphoma and H69 small cell lung cancer cells

被引:0
作者
Shibakura, M [1 ]
Niiya, K
Kiguchi, T
Nakata, Y
Tanimoto, M
机构
[1] Okayama Univ, Sch Med, Dept Hlth Sci, Okayama 7008558, Japan
[2] Okayama Univ, Grad Sch Med & Dent, Dept Hematol Oncol & Resp Med, Okayama 7008558, Japan
关键词
CPT; SN38; UPA; RC-K8; H69;
D O I
暂无
中图分类号
R-3 [医学研究方法]; R3 [基础医学];
学科分类号
1001 ;
摘要
We previously reported that anthracyclines, which could generate reactive oxygen species (ROS), could induce the urokinase-type plasminogen activator (uPA) gene expression in human RC-K8 malignant lymphoma cells and in H69 small cell lung cancer (SCLC) cells. In screening other uPA-inducible anti-cancer agents, we found that camptothecin (CPT) and its derivative, SN38, could induce uPA in RC-K8 and H69 cells. CPT and SN38, which are also used for the treatment of lymphoma and SCLC, significantly increased the uPA accumulation in the conditioned media of both cells in a dose-dependent manner. The maximum induction of uPA mRNA levels was observed 24 h after stimulation. Pretreatment with pyrrolidine dithiocarbamate (PDTC), an anti-oxidant, inhibited the CPT-induced uPA mRNA expression. Thus, CPT induces uPA through gene expression, and, therefore, CPT may influence the tumor-cell biology by up-regulating the uPA/plasmin system.
引用
收藏
页码:223 / 227
页数:5
相关论文
共 25 条
[1]   UROKINASE AND TYPE-I PLASMINOGEN-ACTIVATOR INHIBITOR PRODUCTION BY NORMAL HUMAN HEPATOCYTES - MODULATION BY INFLAMMATORY AGENTS [J].
BUSSO, N ;
NICODEME, E ;
CHESNE, C ;
GUILLOUZO, A ;
BELIN, D ;
HYAFIL, F .
HEPATOLOGY, 1994, 20 (01) :186-190
[2]  
Cirillo G, 1999, MOL CELL BIOL, V19, P6240
[3]  
Creagh EM, 1999, IMMUNOLOGY, V97, P36
[4]   Role of peroxide and superoxide anion during tumour cell apoptosis [J].
Gorman, A ;
McGowan, A ;
Cotter, TG .
FEBS LETTERS, 1997, 404 (01) :27-33
[5]   Activator protein 1 (AP-1)- and nuclear factor κB (NF-κB)-dependent transcriptional events in carcinogenesis [J].
Hsu, TC ;
Young, MR ;
Cmarik, J ;
Colburn, NH .
FREE RADICAL BIOLOGY AND MEDICINE, 2000, 28 (09) :1338-1348
[6]  
Kehrer DFS, 2000, CLIN CANCER RES, V6, P3451
[7]   Induction of urokinase-type plasminogen activator by the anthracycline antibiotic in human RC-K8 lymphoma and H69 lung-carcinoma cells [J].
Kiguchi, T ;
Niiya, K ;
Shibakura, M ;
Miyazono, T ;
Shinagawa, K ;
Ishimaru, F ;
Kiura, K ;
Ikeda, K ;
Nakata, Y ;
Harada, M .
INTERNATIONAL JOURNAL OF CANCER, 2001, 93 (06) :792-797
[8]  
KUBONISHI I, 1986, CANCER, V58, P1453, DOI 10.1002/1097-0142(19861001)58:7<1453::AID-CNCR2820580713>3.0.CO
[9]  
2-B
[10]   Phase II study of irinotecan combined with cisplatin in patients with previously untreated small-cell lung cancer [J].
Kudoh, S ;
Fujiwara, Y ;
Takada, Y ;
Yamamoto, H ;
Kinoshita, A ;
Ariyoshi, Y ;
Furuse, K ;
Fukuoka, M ;
Takada, M ;
Ikegami, H ;
Nishikawa, H ;
Nakajima, S ;
Hoso, T ;
Higashino, K ;
Takahara, J ;
Kamei, M ;
Yamakido, M ;
Ryu, S ;
Hara, N ;
Fukuda, M ;
Kinuwaki, E ;
Tanaka, F ;
Senba, H ;
Araki, J .
JOURNAL OF CLINICAL ONCOLOGY, 1998, 16 (03) :1068-1074